Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in GPCR signalling are implicated in the pathogenesis and treatment of neuropsychiatric55, immunological56, gastrointestinal57,58, cardiac59, renal, hormonal, infectious60 and many other disorders53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [55]
In the citing paper
“most clinically effective antipsychotics also exhibit a myriad of other actions that contribute to both therapeutic and side-effect profiles [359,360].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [360]
In the citing paper
“This often generates beneficial therapeutic activities,102 due to additive or synergistic pharmacological effects.103”
From QSAR without borders (2020) · cites this paper as [102]
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia
Lewis, C. M., Levinson, D. F., Wise, L. H., DeLisi, L. E., Straub, R. E., Hovatta, I., Williams, N. M., Schwab, S. G., Pulver, A. E., Faraone, S. V., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376549 · Cited by 1,137
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Self-citationBurris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Research works printed but not linked: 1
- Hemrick–Luecke, S. et al. Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors and in antipsychotic models. Proc. Soc. Neurosci. 894.9 (2002).
Cited by
Items 301–400 of 1,000
Developing nociceptor-selective treatments for acute and chronic pain
Jayakar, S. S., Shim, J., Jo, S., Bean, B. P., Singeç, I., & Woolf, C. J. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9837 · Cited by 63
Getting in Touch with the Clathrin Terminal Domain
Lemmon, S. K., & Traub, L. M. (2012) · Traffic · doi:10.1111/j.1600-0854.2011.01321.x · Cited by 60
Antidepressants are modifiers of lipid bilayer properties
Kapoor, R., Peyear, T. A., Koeppe, R. E., & Andersen, O. S. (2019) · The Journal of General Physiology · doi:10.1085/jgp.201812263 · Cited by 63
Epigenetic signaling in schizophrenia
Ibi, D., & González-Maeso, J. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.06.003 · Cited by 61
Defining and characterizing drug/compound function
Kenakin, T., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.033 · Cited by 69
Update on GPCR-based targets for the development of novel antidepressants
Mantas, I., Saarinen, M., Xu, Z., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01040-1 · Cited by 55
AI-Driven Polypharmacology in Small-Molecule Drug Discovery
Abdelsayed, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146996 · Cited by 70
Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson’s Disease
Jaiteh, M., Zeifman, A. A., Saarinen, M., Svenningsson, P., Brea, J. M., Loza, M. I., & Carlsson, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00204 · Cited by 63
Nichols, C. D. (2009) · Frontiers in Molecular Neuroscience · doi:10.3389/neuro.02.016.2009 · Cited by 59
Ji, H.-F., Kong, D.-X., Shen, L., Chen, L.-L., Ma, B.-G., & Zhang, H.-Y. (2007) · Genome Biology · doi:10.1186/gb-2007-8-8-r176 · Cited by 59
Anesthetic Considerations for Patients on Psychotropic Drug Therapies
Harbell, M. W., Dumitrascu, C., Bettini, L. M., Yu, S., Thiele, C. M., & Koyyalamudi, V. (2021) · Neurology International · doi:10.3390/neurolint13040062 · Cited by 64
Möller, M., Swanepoel, T., & Harvey, B. H. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn5003368 · Cited by 67
Cao, X., Zhang, Y., Chen, Y., Qiu, Y., Yu, M., Xu, X., Liu, X., Liu, B., Zhang, L., & Zhang, G. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01096 · Cited by 60
Chávez-Castillo, M., Núñez, V., Nava, M., Ortega, Á., Rojas, M., Bermúdez, V., & Rojas, J. (2019) · Advances in Pharmacological Sciences · doi:10.1155/2019/7943481 · Cited by 71
Novel Ergopeptides as Dual Ligands for Adenosine and Dopamine Receptors
Vendrell, M., Angulo-Pueyo, E., Casadó, V., Lluís, C., Franco, R., Alberício, F., & Royo, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060947x · Cited by 60
Li, C., Chen, M., Sang, M., Liu, X., Wu, W., & Li, B. (2013) · Gene · doi:10.1016/j.gene.2013.01.061 · Cited by 59
Humbert‐Claude, M., Davenas, E., Gbahou, F., Vincent, L., & Arrang, J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2471-5 · Cited by 64
Geldenhuys, W. J., & Van der Schyf, C. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.744746 · Cited by 57
Antipsychotics as environmental pollutants: An underrated threat?
Argaluza, J. E., Muñoz, J. L., Morera‐Herreras, T., Hernandez, R., Medrano, J., Domingo‐Echaburu, S., Barceló, ., Orive, G., & Lertxundi, U. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.144634 · Cited by 58
In Silico Receptorome Screening of Antipsychotic Drugs
Vidal, D., & Mestres, J. (2010) · Molecular Informatics · doi:10.1002/minf.201000055 · Cited by 62
Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?
Williams, M. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.171751 · Cited by 65
Folate receptor-β constitutes a marker for human proinflammatory monocytes
Shen, J., Hilgenbrink, A. R., Xia, W. G., Feng, Y., Dimitrov, D. S., Lockwood, M. B., Amato, R. J., & Low, P. S. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ab0713-372r · Cited by 66
Clozapine and GABA transmission in schizophrenia disease models
O'Connor, W. T., & O’Shea, S. D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.005 · Cited by 62
Turning promiscuous kinase inhibitors into safer drugs
Zhang, X., Crespo, A., & Fernández, A. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.02.008 · Cited by 58
Identification of G protein-coupled receptors in the pea aphid, Acyrthosiphon pisum
Li, C., Yun, X., Hu, X., Zhang, Y., Sang, M., Liu, X., Wu, W., & Li, B. (2013) · Genomics · doi:10.1016/j.ygeno.2013.06.003 · Cited by 57
Atypical antipsychotics and diabetic ketoacidosis: a review
Guenette, M. D., Hahn, M., Cohn, T. A., Teo, C., & Remington, G. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2982-3 · Cited by 60
Evidence-Based and Quantitative Prioritization of Tool Compounds in Phenotypic Drug Discovery
Wang, Y., Cornett, A., King, F., Mao, Y., Nigsch, F., PARIS, C. G., McAllister, G., & Jenkins, J. L. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.05.016 · Cited by 62
Ahmed, M. R., Gurevich, V. V., Dalby, K. N., Benovic, J., & Gurevich, E. V. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131987 · Cited by 57
Bianchi, M. T., Pathmanathan, J. S., & Cash, S. S. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.09.049 · Cited by 59
p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling
Sheffler, D. J., Kroeze, W. K., Garcia, B. G., Deutch, A. Y., Hufeisen, S. J., Leahy, P. S., Brüning, J. C., & Roth, B. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600585103 · Cited by 60
Self-citationIntegrated mechanistic and data-driven modelling for multivariate analysis of signalling pathways
Hua, F., Hautaniemi, S., Yokoo, R., & Lauffenburger, D. A. (2006) · Journal of The Royal Society Interface · doi:10.1098/rsif.2005.0109 · Cited by 63
Recent Advances in the Rational Drug Design Based on Multi-target Ligands
Yang, T., Sui, X., Yu, B., Shen, Y., & Cong, H. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200102120652 · Cited by 62
Wu, Z., Peng, Y., Yu, Z., Li, W., Liu, G., & Tang, Y. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00291 · Cited by 61
Ge, J., Peng, L., Cheng, J., Pan, C., Tang, J., Chen, F., & Li, J. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.028 · Cited by 58
Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists
Chen, X., McCorvy, J. D., Fischer, M. G., Butler, K. V., Shen, Y., Roth, B. L., & Jin, J. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01208 · Cited by 57
Self-citationA group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice
Wolf, K., Kühn, H., Boehm, F., Gebhardt, L., Glaudo, M., Agelopoulos, K., Ständer, S., Ectors, P., Zahn, D., Riedel, Y. K., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.12.655 · Cited by 55
Simplified proteomics approach to discover protein–ligand interactions
Chang, Y., Schlebach, J. P., VerHeul, R., & Park, C. (2012) · Protein Science · doi:10.1002/pro.2112 · Cited by 55
Contrasting Typical and Atypical Antipsychotic Drugs
Meltzer, H. Y., & Gadaleta, E. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200051 · Cited by 68
Selent, J., López, L., Sanz, F., & Pastor, M. (2008) · ChemMedChem · doi:10.1002/cmdc.200800074 · Cited by 54
Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders
Bawa, P., Pradeep, P., Kumar, P., Choonara, Y. E., Modi, G., & Pillay, V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.001 · Cited by 56
Lim, C.-S., Hoang, E. T., Viar, K. E., Stornetta, R. L., Scott, M. M., & Zhu, J. J. (2014) · Genes & Development · doi:10.1101/gad.232470.113 · Cited by 56
Flexible scaffold-based cheminformatics approach for polypharmacological drug design
Chen, Z., Yu, J., Wang, H., Xu, P., Fan, L., Sun, F., Huang, S., Zhang, P., Huang, H., Gu, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.034 · Cited by 54
Wallach, I., Jaitly, N., & Lilien, R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012063 · Cited by 53
Psychiatric Drugs Bind to Classical Targets Within Early Exocytotic Pathways: Therapeutic Effects
Lester, H. A., Miwa, J. M., & Srinivasan, R. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.020 · Cited by 53
Vehof, J., Risselada, A., Hadithy, A. F. Y. A., Burger, H., Snieder, H., Wilffert, B., Arends, J., Wunderink, L., Knegtering, H., Wiersma, D., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2211-x · Cited by 53
Advances in the Application of Machine Learning Techniques in Drug Discovery, Design and Development
Barrett, S. J., & Langdon, W. B. (2006) · Advances in intelligent and soft computing · doi:10.1007/978-3-540-36266-1_10 · Cited by 59
Anticipating drug side effects by comparative pharmacology
García-Serna, R., & Mestres, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.509343 · Cited by 54
Studies towards the identification of a new generation of atypical antipsychotic agents
Garzya, V., Forbes, I. T., Gribble, A. D., Hadley, M. S., Lightfoot, A. P., Payne, A. H., Smith, A. B., Douglas, S. E., Cooper, D. G., Stansfield, I. G., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.036 · Cited by 55
Minai, R., Matsuo, Y., Onuki, H., & Hirota, H. (2008) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21933 · Cited by 52
5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice
Pogorelov, V. M., Rodriguiz, R. M., Cheng, J., Huang, M., Schmerberg, C. M., Meltzer, H. Y., Roth, B. L., Kozikowski, A. P., & Wetsel, W. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.52 · Cited by 55
Self-citationEmerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era
Marino, M. J., Knutsen, L. J. S., & Williams, M. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701094q · Cited by 56
Systems Biology Approaches and Tools for Analysis of Interactomes and Multi-target Drugs
Schrattenholz, A. S., Groebe, K., & Šoškić, V. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-800-3_2 · Cited by 55
Ivachtchenko, A. V., Frolov, E. B., Mitkin, O. D., Kysil, V. M., Khvat, A. V., Okun, I. M., & Tkachenko, S. E. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.128 · Cited by 57
Structural studies of serotonin receptor family
Parajulee, A., & Kim, K. (2023) · BMB Reports · doi:10.5483/bmbrep.2023-0147 · Cited by 58
Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108107 · Cited by 61
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas
Ehrman, T. M., Barlow, D. J., & Hylands, P. J. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.070 · Cited by 55
Heterobivalent Agents Targeting PSMA and Integrin-αvβ3
Shallal, H. M., Minn, I., Banerjee, S. R., Lisok, A., Mease, R. C., & Pomper, M. G. (2014) · Bioconjugate Chemistry · doi:10.1021/bc4005377 · Cited by 51
Aberrant Expression of Long Non-Coding RNAs in Schizophrenia Patients
Chen, S., Sun, X., Niu, W., Kong, L., He, M., Li, W., Zhong, A., Lu, J. Z., & Zhang, L.-Y. (2016) · Medical Science Monitor · doi:10.12659/msm.896927 · Cited by 51
Yu, Q., Liu, Y., Zhu, Y., Wang, Y.-Y., Li, Q., & Yin, D. (2019) · Brain Structure and Function · doi:10.1007/s00429-018-01824-2 · Cited by 54
Davies, M. A., Setola, V., Strachan, R. T., Sheffler, D. J., Salay, E., Hufeisen, S. J., & Roth, B. L. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500342 · Cited by 53
Self-citationSystems pharmacology strategies for anticancer drug discovery based on natural products
Luo, F., Gu, J., Chen, L., & Xu, X. (2014) · Molecular BioSystems · doi:10.1039/c4mb00105b · Cited by 52
Minzenberg, M., & Leuchter, A. F. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.067 · Cited by 55
Automated design and optimization of multitarget schizophrenia drug candidates by deep learning
Tan, X., Jiang, X., Yang, H., Zhong, F., Li, X., Xiong, Z., Li, Z., Liu, X., Chen, C., Zhao, Q., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112572 · Cited by 52
Mechanisms and Genetics of Antipsychotic-Associated Weight Gain
Balt, S., Galloway, G., Baggott, M. J., Schwartz, Z., & Mendelson, J. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.97 · Cited by 56
Structural Insights Accelerate the Discovery of Opioid Alternatives
Che, T., & Roth, B. L. (2021) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061620-044044 · Cited by 51
Self-citationMolecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
Tuck, J. R., Dunlap, L. E., Khatib, Y. A., Hatzipantelis, C. J., Novak, S. W., Rahn, R. M., Davis, A. R., Mosswood, A., Vernier, A. M. M., Fenton, E. M., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416106122 · Cited by 50
Schlessinger, A., Wittwer, M., Dahlin, A., Khuri, N., Bonomi, M., Fan, H., Giacomini, K. M., & Šali, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.388157 · Cited by 50
Wierońska, J. M., Zorn, S. H., Doller, D., & Pilc, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.007 · Cited by 53
DIABETIC KETOACIDOSIS ASSOCIATED WITH ANTIPSYCHOTIC DRUGS: CASE REPORTS AND A REVIEW OF LITERATURE
Vuk, A., Kuzman, M. R., Baretić, M., & Osvatić, M. M. (2017) · Psychiatria Danubina · doi:10.24869/psyd.2017.121 · Cited by 50
Promiscuous drugs as therapeutics for chemokine receptors
Horuk, R. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000921 · Cited by 50
Setola, V., & Roth, B. L. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.377 · Cited by 48
Self-citationLacosamide Isothiocyanate-Based Agents: Novel Agents To Target and Identify Lacosamide Receptors
Park, K. D., Morieux, P., Salomé, C., Cotten, S. W., Reamtong, O., Eyers, C. E., Gaskell, S. J., Stables, J. P., Liu, R., & Kohn, H. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9012054 · Cited by 47
Nuss, A. B., Ejendal, K. F. K., Doyle, T. B., Meyer, J. M., Lang, E. G., Watts, V. J., & Hill, C. A. (2015) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003515 · Cited by 50
Flood, D. G., Marek, G. J., & Williams, M. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.021 · Cited by 49
Chemogenetics—A Transformational and Translational Platform
English, J. G., & Roth, B. L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1921 · Cited by 44
Self-citationOtero, E., Vergara, S., Robledo, S. M., Cardona, W., Cardá, M., Vélez, I. D., Rojas, C. A., & Otálvaro, F. (2014) · Molecules · doi:10.3390/molecules190913251 · Cited by 46
In Vitro and In Vivo Characterization of the Alkaloid Nuciferine
Farrell, M. S., McCorvy, J. D., Huang, X., Urban, D. J., White, K. L., Giguère, P. M., Doak, A. K., Bernstein, A. I., Stout, K. A., Park, S. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150602 · Cited by 51
Self-citationSelectivity Challenges in Docking Screens for GPCR Targets and Antitargets
Weiss, D. R., Karpiak, J., Huang, X.-P., Sassano, M. F., Lyu, J., Roth, B. L., & Shoichet, B. K. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00718 · Cited by 43
Self-citationUsing sigma-ligands as part of a multi-receptor approach to target diseases of the brain
Brimson, J. M., Brimson, S., Chomchoei, C., & Tencomnao, T. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1805435 · Cited by 46
Zong, D., Zielinska-Chomej, K., Juntti, T., Mörk, B., Lewensohn, R., Hååg, P., & Viktorsson, K. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.56 · Cited by 45
Kargieman, L., Riga, M. S., Artigas, F., & Celada, P. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.249 · Cited by 45
α2-Adrenoceptors are targets for antipsychotic drugs
Brosda, J., Jantschak, F., & Pertz, H. H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3459-8 · Cited by 52
Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment
Huang, X., & Song, X. (2018) · Medicinal Research Reviews · doi:10.1002/med.21512 · Cited by 47
Evaluation of in vitro neuronal platforms as surrogates for in vivo whole brain systems
Belle, A. M., Enright, H. A., Sales, A. P., Kulp, K. S., Osburn, J. J., Kuhn, E. A., Fischer, N. O., & Wheeler, E. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-28950-5 · Cited by 51
Perspectives on Drug Repurposing
Schcolnik‐Cabrera, A., Juárez-López, D., & Dueñas‐González, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200831141337 · Cited by 47
Tian, S., Li, Y., Li, D., Xu, X., Wang, J., Zhang, Q., & Hou, T. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400146u · Cited by 46
Defining the Role of Pharmacology in the Emerging World of Translational Research
Enna, S. J., & Williams, M. J. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57001-3 · Cited by 49
Anttila, S. A. K., Kampman, O., Illi, A., Rontu, R., Lehtimäki, T. J., & Leinonen, E. V. J. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-22 · Cited by 44
Composition and applications of focus libraries to phenotypic assays
Wassermann, A. M., Camargo, L. M., & Auld, D. S. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00164 · Cited by 42
Structural and Functional View of Polypharmacology
Moya‐García, A. A., Adeyelu, T. T., Krüger, F. A., Dawson, N. L., Lees, J., Overington, J. P., Orengo, C. A., & Ranea, J. A. G. (2017) · Scientific Reports · doi:10.1038/s41598-017-10012-x · Cited by 47
WOOD, M., & Wren, P. B. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00911-4 · Cited by 46
Cilia, J., Hatcher, P., Reavill, C., & Jones, D. N. C. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077718 · Cited by 40
Dahan, L., Husum, H., Mnie‐Filali, O., Arnt, J., Hertel, P., & Haddjeri, N. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089586 · Cited by 46
Chloroquine–astemizole hybrids with potent in vitro and in vivo antiplasmodial activity
Musonda, C. C., Whitlock, G. A., Witty, M. J., Brun, R., & Kaiser, M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.047 · Cited by 44
Davis, R. E., Vanover, K. E., Zhou, Y., Brašić, J. R., Guevara, M. C., Bisuna, B., Ye, W., Raymont, V., Willis, W. D., Kumar, A., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3922-1 · Cited by 46
Sheinerman, F. B., Giraud, E., & Laoui, A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.074 · Cited by 45
Modelling olanzapine-induced weight gain in rats
van der Zwaal, E. M., Janhunen, S. K., la Fleur, S. E., & Adan, R. A. H. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571300093x · Cited by 46
Affective responses across psychiatric disorders—A dimensional approach
Hägele, C., Friedel, E., Schlagenhauf, F., Sterzer, P., Beck, A., Bermpohl, F., Stoy, M., Held-Poschardt, D., Wittmann, A., Ströhle, A., et al. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.04.037 · Cited by 46
Dilly, S. J., Clark, A. J., Marsh, A., Mitchell, D. A., Cain, R. M., Fishwick, C. W. G., & Taylor, P. C. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.042 · Cited by 43
A Scalable, Multiplexed Assay for Decoding GPCR-Ligand Interactions with RNA Sequencing
Jones, E. M., Jajoo, R., Cancilla, D., Lubock, N. B., Wang, J., Satyadi, M., Chong, R., de March, C. A., Bloom, J. S., Matsunami, H., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.02.009 · Cited by 46
Metadata
- Authors
- Roth, B. L., Sheffler, D. J., & Kroeze, W. K.
- Affiliations
- Case Western Reserve University (US)
- Corresponding author
- Roth, Bryan L.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 353-359
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2122995608
- Cited by
- 1,155
- References
- 63
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 37 · 2023: 39 · 2022: 47 · 2021: 49 · 2020: 49 · 2019: 63 · 2018: 46 · 2017: 42 · 2016: 61 · 2015: 65 · 2014: 58 · 2013: 73 · 2012: 83
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- magic bullet, polygenic disease, mood disorders, schizophrenia, depression, bipolar disorder, central nervous system disorders, drug target selectivity, polypharmacology, antipsychotic drug development
- MeSH terms
- Humans, Schizophrenia, Antipsychotic Agents, Drugs, Investigational, Comorbidity, Mood Disorders, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.